anti-CD38 therapy

Meletios Dimopoulos MD, Chair of Clinical Therapeutics at the University of Athens, discusses early findings from the phase 1b LINKER-MM2 trial presented at ASH 2025. The study reveals high clinical response rates for the B-Cell Maturation Antigen bispecific antibody linvoseltamab when combined with anti-CD38 therapy in patients with relapsed/refractory multiple myeloma. These preliminary safety and efficacy data support further development of this promising combination for MM treatment.